OncoBayes OB-001 preclinical data show potential to overcome ADC resistance and TKI brain penetration
OncoBayes announced successful preclinical work with OB-001, demonstrating its potential to address ADC resistance and improve TKI brain penetration. In mouse studies, OB-001 increased brain exposure of kinase inhibitors by almost 400% without significantly impacting systemic exposure.